Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target

Stock Track

04/01

3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.

CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.

While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1147015943"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147015943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147015943?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 14:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147015943","market":"hk","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target","media":"Stock Track","content":"<p>3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.</p><p>CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.</p><p>While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 11.66% Intraday as CICC Maintains Outperform Rating with 61% Upside Target\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-01 14:29</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.</p><p>CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.</p><p>While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生製藥","start_time":0,"source_url":"","article_id":"1147015943","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147015943","pubTimestamp":1775024973,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股轨迹|三生制药盘中大涨11.66%中金维持跑赢大盘评级目标61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock surged 11.66% during intraday trading on Wednesday, following the release of a positive research report from CICC.CICC maintained its Outperform rating on 3SBIO with a target price of HK$36.5, implying a 61% upside potential from current levels. The investment bank highlighted the smooth progress of the company's 707 collaboration with Pfizer, which is rapidly advancing overseas clinical trials, including global Phase III trials for NSCLC and CRC. CICC also noted the company's robust R&D pipeline, covering both oncology and autoimmune indications.While CICC adjusted its 2026 net profit forecast due to timing changes in financial statement recognition for out-licensing revenue, the firm remains optimistic about 707's potential to become a cornerstone next-generation I/O therapy. The report also mentioned recent product approvals and new drug applications that are expected to contribute to future revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}